Further subgroup analysis suggested that TNFAIP3 mutation predicted poor OS for T‐ALL patients who underwent chemotherapy only (p < 0.001), and it was positively correlated with high risk and early T‐cell precursor ALL (ETP‐ALL) in two independent validation datasets (NFH and PRJCA002270). Here, TNFAIP3 is linked to acute lymphoblastic leukemia.